Oxford Textbook of Rheumatoid Arthritis

This brand new textbook of rheumatoid arthritis (RA) is an important addition to the Oxford Textbooks in Rheumatology series, and provides a comprehensive overview of both the scientific and clinical aspects of the disease. Divided into eight sections - from the history, diagnosis, and epidemiology of the disease, through the pathogenesis, clinical presentation, and assessment to treatments and management strategies, both drug- and non-drug based - each chapter is written by leading clinicians and scientists in the field to deliver a contemporary view of RA.

During the past two decades there have been revolutionary changes in the understanding and management of rheumatoid arthritis, in particular the development of biological treatments. This has had wide-ranging effects on almost all aspects of treatment, from effectiveness and intensity to the nature and the cost. Providing a comprehensive account of the modern ideas about the disease, the Oxford Textbook of Rheumatoid Arthritis is a key new addition to the literature, with each chapter providing a detailed background, key recent advances, and areas of doubt and future developments.

Featuring over 170 photographs, radiological images, and clinical charts to aid both diagnosis and illustrate the rationale behind key scientific studies, this new title will prove an indispensable resource for specialist rheumatologists, trainees in rheumatology, and other members of the multi-disciplinary team.

David L. Scott, Emeritus Professor Of Rheumatology, Centre for Rheumatic Diseases, King's College London, London, UK,James Galloway, Senior Lecturer in Rheumatology, King's College London and, Honorary Consultant Rheumatologist, King's College London, London, UK,Andrew Cope, Versus Arthritis Professor of Rheumatology, King's College London and, Honorary Consultant Rheumatologist, Guy's and St Thomas' Hospital, London, UK,Arthur Pratt, Clinical Senior Lecturer in Rheumatology, University of Newcastle, and Honorary Consultant Rheumatologist, Freeman Hospital, Newcastle, UK,Vibeke Strand, Biopharmaceutical Consultant and Adjunct Clinical Professor, Division of Immunology and Rheumatology, Stanford University, Palo Alto, USA

David L. Scott is Professor of Clinical Rheumatology at King's College London. He trained in medicine and rheumatology in Leeds and Birmingham and subsequently held a fellowship at St Bartholomew's Hospital in London. His current academic focus spans the outcomes of rheumatoid arthritis and the impact of intensive treatment in improving outcomes in clinical trials.


James Galloway is Senior Lecturer in Rheumatology at King's College London and Honorary Consultant Rheumatologist at King's College Hospital. After training in medicine and rheumatology in Bristol and Manchester he held a fellowship at the Arthritis Research UK Epidemiology Unit in Manchester. His current academic focus is on large observational studies of arthritis and treatment risks including infections

Andrew Cope is Arthritis Research UK Professor of Rheumatology at King's College London and Honorary Consultant Rheumatologist at Guy's and St Thomas's Hospital. After training in medicine and rheumatology in London he held fellowships at the Kennedy Institute of Rheumatology and Stanford University. His current academic focus spans laboratory studies, clinical trials and observational studies with an emphasis on understanding the immunobiology of inflammatory arthritis.


Arthur Pratt is Clinical Fellow in the Institute of Cellular Medicine and Honorary Consultant Rheumatologist at the Freeman Hospital in Newcastle. He trained in medicine and rheumatology in Leeds and Newcastle. Subsequently he was a training fellow and National Institute for Health Clinical Lecturer at Newcastle University. His current academic focus is clinical and laboratory assessments and predictors in early inflammatory arthritis.


Vibeke Strand is Adjunct Clinical Professor, in the Division of Immunology and Rheumatology at Stanford University. She is a clinical rheumatologist and acts as a consultant in biopharmaceutics, clinical research, and regulatory affairs to many pharmaceutical and biotech companies. After graduating from Swarthmore College she trained in medicine and rheumatology at University of California San Francisco School of Medicine. Her current academic focus spans clinical trial design, development of outcome measures with an emphasis on patient reported outcomes and regulatory strategies leading to approval of new agents for treatment of autoimmune diseases. She gives particular emphasis to translating basic research findings into rationally designed clinical trials, evaluating their results and helping patients access new treatments.

1. History, diagnosis, and epidemiology
1. The history of rheumatoid arthritis, David L. Scott
2. Diagnosis, Daniel Aletaha and Helga Radner
3. The descriptive epidemiology of rheumatoid arthritis, James Gwinnutt and Deborah Symmons
4. Modifiable and other risk factors for rheumatoid arthritis: a basis for prevention and better therapy, Lars Klareskog and Lars Alfredsson
2. Pathogenesis
5. Genetics and epigenetics of rheumatoid arthritis, Anne Barton
6. Dysregulation of synovial fibroblasts in rheumatoid arthritis, Thomas Crowley, Jason Turner, Andrew Filer, Andy Clark, and Chris Buckley
7. Autoantibodies in rheumatoid arthritis, Tom W. J. Huizinga
8. Dendritic cells and T cells in rheumatoid arthritis, Soi-Cheng Law, Pascale Wehr, Harriet Purvis, and Ranjeny Thomas
9. Mechanisms of bone and cartilage destruction, Ukrike Steffen and Georg Schett
10. Cytokines and other mediators, Marina Frleta-Gilchrist and Iain B. McInnes
3. Clinical presentation
11. Clinical features of rheumatoid arthritis, Annette van der Helm-van Mil
12. Pre-rheumatoid arthritis, Karim Raza, Catherine McGrath, Laurette van Boheemen, and Dirkjan van Schaardenburg
13. Non-articular manifestations of rheumatoid arthritis, Katherine MacDonald, Jennifer Hannah, and James Galloway
14. Comorbidity in rheumatoid arthritis, Kimme Hyrich and Sarah Skeoch
4. Disease assessment
15. Disease activity assessment in rheumatoid arthritis, Josef Smolen
16. Synovial biopsies, Douglas Veale and Ursula Fearon
17. Radiography in rheumatoid arthritis, Charles Peterfy, Philip Conaghan, and Mikkel ?stergaard
18. Ultrasound in rheumatoid arthritis, Andrew Filer, Maria Antonietta D'Agostino, and Ilfita Sahbudin
19. MRI in rheumatoid arthritis, Charles Peterfy, Philip Conaghan, and Mikkel ?stergaard
5. Impact on life
20. Patient physical function in rheumatoid arthritis, Kathryn A. Gibson and Theodore Pincus
21. Fatigue, Emma Dures and Neil Basu
22. Health economics, David L. Scott and Allan Wailoo
23. Rheumatoid arthritis and work, Suzanne Verstappen, Cheryl Jones, Abdullah Houssien, and James Galloway
6. Non-drug treatments
24. Exercise, Lindsay Bearne and Christina Opava
25. Foot health, Heidi Siddle and Anthony Redmond
26. Occupational therapy, Alison Hammond, Joanne Adams, and Yeliz Prior
27. Self-management: a patient's perspective, Marieke M.J.H. Voshaar
7. Drug treatments
28. Analgesics, Opioids, and NSAIDs, Mark D Russell and Nidhi Sofat
29. Glucocorticoids, Johannes W. G. Jacobs, Marlies C. van der Goes, Johannes W. J. Bijlsma, and Jos? A. P. da Silva
30. Conventional disease modifying drugs, David L. Scott
31. Tumour necrosis factor inhibitors, Peter Taylor and Nehal Narayan
32. Interleukin-6 inhibitors, Neelam Hassan and Ernest Choy
33. B-cell therapies, Yuzaiful Yusof, Edward Vital, and Maya Buch
34. Biosimilars, Vibeke Strand, Jeffrey Kaine, and John Isaacs
35. Immunogenicity in response to biologic agents, Meghna Jani, John Isaacs, and Vibeke Strand
36. The use of JAK inhibitors in the treatment of rheumatoid arthritis, Katie Bechman, James Galloway, and Peter Taylor
37. Combination therapy in rheumatoid arthritis, Ben G.T. Coumbe, Elena Nikiphorou, and Tuulikki Sokka-Isler
38. Translation of new therapies: from bench to bedside, Jeremy Sokolove
39. Adverse events in clinical studies in rheumatoid arthritis, James Galloway and Mark Yates
8. Management and outcomes
40. Prevention of rheumatoid arthritis, Tom W. J. Huizinga, Annette van der Helm-van Mil, and Andrew Cope
41. Treatment targets and remission, Kenneth F Baker and Arthur G Pratt
42. Clinical outcomes, David L. Scott
43. Clinical guidelines, Anna-Birgitte Aga, Espen A. Haavardsholm, Till Uhlig, and Tore K. Kvien
44. European biologics registers, Angela Zink and Anja Strangfeld
45. Voluntary patient registries, Jeff Greenberg and Sheetal Patel